
News|Articles|January 1, 2004
As post-tamoxifen therapy, letrozole cuts breast cancer recurrence 43%
Letrozole therapy, in follow-up to 5 years of tamoxifen treatment, significantly improves disease-free survival compared to placebo, according to a study published in The New England Journal of Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Immunotherapy combination of teclistamab and daratumumab heralded as potential 'functional cure' for multiple myeloma | ASH 2025
2
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
3
2025 FDA dermatology approvals: A new gene therapy and two targeted therapies
4
Breakthrough treatments offer hope for melanoma patients
5




















































